Adverum Biotechnologies Prepares for Major Investor Conferences
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is in the spotlight as it gears up to participate in several important investor conferences. These events will showcase the company's innovative approaches and future projects. As a clinical-stage organization, Adverum is at the forefront of gene therapy, aiming to set a new standard for treating common ocular diseases.
Overview of Upcoming Conferences
The company has revealed its involvement in several key events that will facilitate connections with investors and allow them to share their vision moving forward. The conferences include:
H.C. Wainwright 26th Annual Global Investment Conference
Scheduled for a Tuesday in mid-September, Adverum will present at this significant conference at 3:30 p.m. ET. This event provides an opportunity for the company to showcase its groundbreaking projects in gene therapy.
Chardan’s 8th Annual Genetic Medicines Conference
On October 1st, Adverum Biotechnologies will take the stage at this important conference at 8:00 a.m. ET. This event will further highlight the company's progress in genetic therapies.
UBS Virtual Ophthalmology Day
Following the Chardan conference, Adverum will participate in the UBS Virtual Ophthalmology Day on a Wednesday at 10:30 a.m. ET. This virtual format allows for broader engagement as digital participation continues to rise, enabling more people to connect with Adverum's innovations.
Accessing Webcasts
Investors and those interested can access on-demand webcasts of these presentations through the Events and Presentations section on Adverum’s website. Each presentation will be available for replay for at least 30 days, allowing audiences to revisit valuable insights.
About Adverum Biotechnologies
Adverum Biotechnologies is focused on transforming the treatment landscape for ocular diseases through innovative gene therapy. Utilizing its proprietary intravitreal (IVT) platform, the company is developing one-time therapies that could reduce the need for frequent ocular injections. Their leading candidate, ixoberogene soroparvovec (Ixo-vec), targets conditions such as neovascular or wet age-related macular degeneration.
In addition to improving existing treatments, Adverum aims to redefine the standard of care, enhancing patients' quality of life and striving for long-lasting vision restoration. By addressing the limitations of current therapies in the ocular field, Adverum Biotechnologies is well-positioned to make a significant societal impact.
Contact Information
For more information, interested individuals can contact Adverum's Investor Relations via email at ir@adverum.com.
Frequently Asked Questions
What is Adverum Biotechnologies focused on?
Adverum is dedicated to utilizing gene therapy to tackle prevalent ocular diseases, with the goal of providing sustainable treatment options for patients.
When will Adverum participate in investor conferences?
Adverum is set to present at several investor conferences in September and October, where they will provide important updates on their advancements.
How can I access the investor presentations?
The presentations will be available on-demand on Adverum's website in the Events and Presentations section for at least 30 days following each event.
What is ixoberogene soroparvovec?
ixoberogene soroparvovec (Ixo-vec) is Adverum’s leading gene therapy candidate intended for the one-time treatment of wet age-related macular degeneration.
How does Adverum plan to address ocular diseases?
Adverum is focused on developing durable therapies that allow patients to avoid repeated injections, thus simplifying the treatment process and improving patient care.
